Immutep (ASX:IMM) - CEO, Marc Voigt
CEO, Marc Voigt
Source: Terrapinn Asia
Market Herald logo


Be the first with the news that moves the market
  • Biotech company Immutep (IMM) has been granted a patent from the Japanese Patent Office for its eftilagimod alpha (efti) treatment
  • The patent will protect the company’s intellectual property on efti and will expire in December 2034
  • efti is Immutep’s anti-cancer drug, which is designed to treat metastatic breast cancer
  • In a recent clinical trial, efti was shown to have a higher six-month progression-free survival rate over a placebo treatment
  • Immutep is up 5.56 per cent on the market and shares are currently trading for 14.3 cents each

Biotech company Immutep (IMM) has been granted a patent from the Japanese Patent Office for eftilagimod alpha (efti) treatment.

This new patent, titled “Combined Preparations for the Treatment of Cancer,” follows grants in Europe and Australia in 2019.

The patent will protect Immutep’s intellectual property relating to efti and a chemotherapy agent that contains oxaliplatin, carboplatin, and topotecan.

All of these are chemotherapy drugs that treat differing types of cancers and are used together.

This patent expires on December 19 2034.

What is efit?

Efti, which can also be known as IMP321, is Immutep’s anti-cancer drug that is designed to treat metastatic breast cancer.

Metastatic breast cancer is when cancer has spread from the breast and lymph nodes into other parts of the body such as lungs, bones, liver, or brain.

It’s known as the most advanced stage of breast cancer.

In March, Immutep reported on results from a breast cancer trial with 227 metastatic breast cancer patients.

The patients were treated with efti and paclitaxel, an anti-cancer chemotherapy drug and chemotherapy medication, to boost the body’s T-cell immune response against tumours.

T-cells play a major role in defending the body against viruses, parasites, and bacteria, and those with a low count of T-cells generally have a harder time fighting off infections.

Results from this trial showed that at the six-month mark, progression-free survival was in favour of efti (63 per cent) rather than a placebo (54 per cent).

Immutep is up 5.56 per cent on the market and shares are trading for 14.3 cents each at 12:38 pm AEST.

IMM by the numbers
More From The Market Herald
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.
The Market Herald Video

" Proteomics International (ASX:PIQ) to raise $8m for Promarker development

Proteomics International (ASX:PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further…